WC
The startup has developed a Patient-Derived Explants (PDEs) platform that profiles tumor responses to cancer immunotherapy, allowing for personalized treatment selection. This technology enhances patient survival rates by providing precise assessments of how individual tumors react to specific therapies.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup has developed a Patient-Derived Explants (PDEs) platform that profiles tumor responses to cancer immunotherapy, allowing for personalized treatment selection. This technology enhances patient survival rates by providing precise assessments of how individual tumors react to specific therapies.